DOI: 10.5061/dryad.bs0p30k
title: Data from: A virtual molecular tumor board platform to improve efficiency and scalability of delivering precision oncology to physicians and their patients

description: OBJECTIVES: Scalable informatics solutions that provide
 molecularly-tailored treatment recommendations to clinicians are needed to
 streamline Precision Oncology in care settings. MATERIALS AND METHODS: We
 developed a cloud-based virtual molecular tumor board (VMTB) platform that
 included a knowledgebase, scoring model, rules engine, an asynchronous
 virtual chat room and a reporting tool that generated a treatment plan for
 each of the 1725 patients based on their molecular profile, previous
 treatment history, structured trial eligibility criteria, clinically
 relevant cancer gene-variant assertions, biomarker-treatment associations,
 and current treatment guidelines. The VMTB systematically allows clinician
 users to combine expert-curated data and structured data from clinical
 charts along with molecular testing data to develop consensus on
 treatments, especially those that require off-label and clinical trial
 considerations. RESULTS: The VMTB was used as part of the cancer care
 process for a focused subset of 1725 patients referred by advocacy
 organizations wherein resultant personalized reports were successfully
 delivered to treating oncologists. Median turnaround time from data
 receipt to report delivery decreased from 14 days to 4 days over 4 years
 while the volume of cases increased nearly twofold each year. Using a
 novel scoring model for ranking therapy options, oncologists chose to
 implement the VMTB-derived therapies over others, except when pursuing
 immunotherapy options without molecular support. DISCUSSION: VMTBs will
 play an increasingly critical role in precision oncology as the compendium
 of biomarkers and associated therapy options available to a patient
 continues to expand. CONCLUSION: Further development of such clinical
 augmentation tools that systematically combine patient-derived molecular
 data, real world evidence from electronic health records, and expert
 curated knowledgebases on biomarkers with computational tools for ranking
 best treatments can support care pathways at point of care.
description: Pishvaian et
 al.2019_VMTB_JAMIAOpen_Fig4BThe attached csv file
 contains the underlying data for Figure 4B which is described in the
 manuscript as follows - After receiving molecular testing results and past
 medical and treatment history, turnaround time for case review by VMTB
 users decreased from a median of 14 days in 2014 to 4 days in 2018.
 Turnaround time was evaluated as the number of days between starting step
 3 and completing step 8 as described in Figure 1. The solid line
 represents the median turnaround time and dashed lines represent 25th and
 75th percentiles. A significant negative correlation (Spearman’s rho =
 -0.52; p = 2.9 x 10-113) was observed between the year of report delivery
 and the turnaround time.Pishvaian et
 al.2019_VMTB_JAMIAOpen_Fig6AThe attached csv file
 contains the underlying data for Figure 6A, which is described in the
 manuscript as follows - Distribution of the highest ranked therapy option
 chosen by each patient and their treating oncologist (1 per patient,
 lesser ranked implementations omitted).Pishvaian et
 al.2019_VMTB_JAMIAOpen_Fig6BThe attached csv file
 contains the underlying data for Figure 6B, which is described in the
 manuscript as follows - Distribution of therapy option rankings
 implemented that included an immune checkpoint inhibitor
 (PD-1/PD-L1/CTLA-4/OX40 antibody). It is important to note that
 immunotherapy was nearly universally recommended (with or without
 molecular support) but primarily in the context of a clinical trial and
 rarely as an off-label option.